Nadeem Sarwar, Ph.D., specializes in strategies to integrate and apply several sciences to deliver novel, precision medicines from human genetic and related sources. He has established and serves as president of the AiM Institute, which currently has assets in early stage clinical trials, late stage pre-IND and early stage preclinical discovery.
Nadeem’s research has been published in a number of leading medical journals, including the New England Journal of Medicine (NEJM), Journal of the Americam Medical Association (JAMA), and Lancet. He has presented at a variety of international scientific meetings, including the Prix Galien Foundation, American Diabetes Association and Hitachi Innovation. He has been invited to provide expert insights on the role of human genetics in drug discovery and precision medicine for several institutes globally. He obtained his doctorate in molecular & genetic epidemiology at the University of Cambridge (UK), where he studied with Professor John Danesh.